{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:17:19Z","timestamp":1794331039212,"version":"4.9.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Geriatr"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract (<jats:italic>N<\/jats:italic>\u2009=\u2009351)<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Drug-drug interactions (DDIs) are highly prevalent in older patients but little is known about prevalence of DDIs over time. Our main objective was to assess changes in the prevalence and characteristics of drug-drug interactions (DDIs) during a one-year period after hospital admission in older people, and associated risk factors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a sub-study of the European OPERAM trial (OPtimising thERapy to prevent Avoidable hospital admissions in Multimorbid older people), which assessed the effects of a structured medication review (experimental arm) compared to usual care (control arm) on reducing drug-related hospital readmissions. All OPERAM patients (\u226570\u2009years, with multimorbidity and polypharmacy, hospitalized in four centers in Bern, Brussels, Cork and Utrecht between December 2016 and October 2018, followed over 1 year) who were alive at hospital discharge and had full medication data during the index hospitalization (at baseline i.e., enrolment at admission, and at discharge) were included. DDIs were assessed using an international consensus list of potentially clinically significant DDIs in older people. The point-prevalence of DDIs was evaluated at baseline, discharge, and at 2, 6 and 12\u2009months after hospitalization. Logistic regression models were performed to assess independent variables associated with changes in DDIs 2\u2009months after baseline.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 1950 patients (median age 79\u2009years) included, 1045 (54%) had at least one potentially clinically significant DDI at baseline; point-prevalence rates were 58, 57, 56 and 57% at discharge, and 2, 6 and 12\u2009months, respectively. The prevalence increased significantly from baseline to discharge (<jats:italic>P<\/jats:italic>\u2009&lt;\u2009.001 [significant only in the control group]), then remained stable over time (<jats:italic>P<\/jats:italic>for trend .31). The five most common DDIs \u2013all pharmacodynamic in nature\u2013 accounted for 80% of all DDIs and involved drugs that affect potassium concentrations, centrally-acting drugs and antithrombotics. At 2\u2009months, DDIs had increased in 459 (27%) patients and decreased in 331 (19%). The main factor predictive of a change in the prevalence of DDIs was hyperpolypharmacy (\u226510 medications).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>DDIs were very common; their prevalence increased during hospitalization and tended to remain stable thereafter. Medication review may help control this increase and minimize the risk of adverse drug events.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12877-021-02532-z","type":"journal-article","created":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T22:28:11Z","timestamp":1634596091000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Prevalence of drug-drug interactions in older people before and after hospital admission: analysis from the OPERAM trial"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3474-2200","authenticated-orcid":false,"given":"Lor\u00e8ne","family":"Zerah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9verine","family":"Henrard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingeborg","family":"Wilting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"O\u2019Mahony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Rodondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Dalleur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran","family":"Dalton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilma","family":"Knol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Haschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Spinewine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,18]]},"reference":[{"key":"2532_CR1","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/02813430310001806","volume":"21","author":"L Bjerrum","year":"2003","unstructured":"Bjerrum L, Andersen M, Petersen G, Kragstrup J. Exposure to potential drug interactions in primary health care. Scand J Prim Health Care. 2003;21:153\u20138.","journal-title":"Scand J Prim Health Care"},{"key":"2532_CR2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1517\/14740338.2012.631910","volume":"11","author":"L Magro","year":"2012","unstructured":"Magro L, Moretti U, Leone R. Epidemiology and characteristics of adverse drug reactions caused by drug-drug interactions. Expert Opin Drug Saf. 2012;11:83\u201394.","journal-title":"Expert Opin Drug Saf"},{"key":"2532_CR3","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0140-6736(07)61092-7","volume":"370","author":"L Mallet","year":"2007","unstructured":"Mallet L, Spinewine A, Huang A. The challenge of managing drug interactions in elderly people. Lancet. 2007;370:185\u201391.","journal-title":"Lancet."},{"key":"2532_CR4","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s11096-017-0439-1","volume":"39","author":"S S\u00e1nchez-Fidalgo","year":"2017","unstructured":"S\u00e1nchez-Fidalgo S, Guzm\u00e1n-Ramos MI, Galv\u00e1n-Banqueri M, Bernabeu-Wittel M, Santos-Ramos B. Prevalence of drug interactions in elderly patients with multimorbidity in primary care. Int J Clin Pharm. 2017;39:343\u201353.","journal-title":"Int J Clin Pharm"},{"key":"2532_CR5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1136\/ejhpharm-2019-002111","volume":"28","author":"LM de Oliveira","year":"2021","unstructured":"de Oliveira LM, do AC DJ, Nunes A, da Silva Dal Pizzol T. Prevalence of drug interactions in hospitalised elderly patients: a systematic review. Eur J Hosp Pharm Sci Pract. 2021;28:4\u20139.","journal-title":"Eur J Hosp Pharm Sci Pract"},{"key":"2532_CR6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12916-015-0322-7","volume":"13","author":"B Guthrie","year":"2015","unstructured":"Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995\u20132010. BMC Med. 2015;13:74.","journal-title":"BMC Med"},{"key":"2532_CR7","doi-asserted-by":"publisher","first-page":"911","DOI":"10.2165\/00002018-200730100-00009","volume":"30","author":"K Johnell","year":"2007","unstructured":"Johnell K, Klarin I. The relationship between number of drugs and potential drug-drug interactions in the elderly: a study of over 600,000 elderly patients from the Swedish prescribed drug register. Drug Saf. 2007;30:911\u20138.","journal-title":"Drug Saf"},{"key":"2532_CR8","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2165\/00002512-200825020-00006","volume":"25","author":"ML Becker","year":"2008","unstructured":"Becker ML, Visser LE, van Gelder T, Hofman A, Stricker BHC. Increasing exposure to drug-drug interactions between 1992 and 2005 in people aged > or = 55 years. Drugs Aging. 2008;25:145\u201352.","journal-title":"Drugs Aging"},{"key":"2532_CR9","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.amjopharm.2011.10.004","volume":"9","author":"LE Hines","year":"2011","unstructured":"Hines LE, Murphy JE. Potentially harmful drug-drug interactions in the elderly: a review. Am J Geriatr Pharmacother. 2011;9:364\u201377.","journal-title":"Am J Geriatr Pharmacother"},{"key":"2532_CR10","doi-asserted-by":"crossref","unstructured":"Beuscart J-B, Knol W, Cullinan S, Schneider C, Dalleur O, Boland B, et al. International core outcome set for clinical trials of medication review in multi-morbid older patients with polypharmacy. BMC Med. 2018;16:21.","DOI":"10.1186\/s12916-018-1007-9"},{"key":"2532_CR11","doi-asserted-by":"crossref","unstructured":"Anrys P, Petit A-E, Thevelin S, Sallevelt B, Drenth C, Soiza RL, et al. An international consensus list of potentially clinically significant drug-drug interactions in older people. J Am Med Dir Assoc. 2021.","DOI":"10.1016\/j.jamda.2021.03.019"},{"key":"2532_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/jcpt.12502","volume":"42","author":"JT Hanlon","year":"2017","unstructured":"Hanlon JT, Perera S, Newman AB, Thorpe JM, Donohue JM, Simonsick EM, et al. Potential drug-drug and drug-disease interactions in well-functioning community-dwelling older adults. J Clin Pharm Ther. 2017;42:228\u201333.","journal-title":"J Clin Pharm Ther"},{"key":"2532_CR13","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/1440-1681.12081","volume":"40","author":"D Gnjidic","year":"2013","unstructured":"Gnjidic D, Johnell K. Clinical implications from drug-drug and drug-disease interactions in older people. Clin Exp Pharmacol Physiol. 2013;40:320\u20135.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"2532_CR14","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s40264-016-0496-8","volume":"40","author":"K Bykov","year":"2017","unstructured":"Bykov K, Gagne JJ. Generating evidence of clinical outcomes of drug-drug interactions. Drug Saf. 2017;40:101\u20133.","journal-title":"Drug Saf"},{"key":"2532_CR15","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40264-014-0262-8","volume":"38","author":"RT Scheife","year":"2015","unstructured":"Scheife RT, Hines LE, Boyce RD, Chung SP, Momper JD, Sommer CD, et al. Consensus recommendations for systematic evaluation of drug-drug interaction evidence for clinical decision support. Drug Saf. 2015;38:197\u2013206.","journal-title":"Drug Saf"},{"key":"2532_CR16","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/pds.1351","volume":"16","author":"ML Becker","year":"2007","unstructured":"Becker ML, Kallewaard M, Caspers PWJ, Visser LE, Leufkens HGM, Stricker BHC. Hospitalisations and emergency department visits due to drug-drug interactions: a literature review. Pharmacoepidemiol Drug Saf. 2007;16:641\u201351.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2532_CR17","doi-asserted-by":"publisher","first-page":"19711","DOI":"10.18632\/aging.104018","volume":"12","author":"F Swart","year":"2020","unstructured":"Swart F, Bianchi G, Lenzi J, Iommi M, Maestri L, Raschi E, et al. Risk of hospitalization from drug-drug interactions in the elderly: real-world evidence in a large administrative database. Aging. 2020;12:19711\u201339.","journal-title":"Aging."},{"key":"2532_CR18","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/pds.3592","volume":"23","author":"S Dechanont","year":"2014","unstructured":"Dechanont S, Maphanta S, Butthum B, Kongkaew C. Hospital admissions\/visits associated with drug-drug interactions: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2014;23:489\u201397.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2532_CR19","doi-asserted-by":"publisher","first-page":"n1585","DOI":"10.1136\/bmj.n1585","volume":"374","author":"MR Blum","year":"2021","unstructured":"Blum MR, Sallevelt BTGM, Spinewine A, O\u2019Mahony D, Moutzouri E, Feller M, et al. Optimizing therapy to prevent avoidable hospital admissions in multimorbid older adults (OPERAM): cluster randomised controlled trial. BMJ. 2021;374:n1585.","journal-title":"BMJ."},{"key":"2532_CR20","doi-asserted-by":"publisher","first-page":"e026769","DOI":"10.1136\/bmjopen-2019-032510","volume":"9","author":"L Adam","year":"2019","unstructured":"Adam L, Moutzouri E, Baumgartner C, Loewe AL, Feller M, M\u2019Rabet-Bensalah K, et al. Rationale and design of OPtimising thERapy to prevent avoidable hospital admissions in multimorbid older people (OPERAM): a cluster randomised controlled trial. BMJ Open. 2019;9:e026769.","journal-title":"BMJ Open"},{"key":"2532_CR21","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1111\/bcp.13716","volume":"84","author":"S Thevelin","year":"2018","unstructured":"Thevelin S, Spinewine A, Beuscart J-B, Boland B, Marien S, Vaillant F, et al. Development of a standardized chart review method to identify drug-related hospital admissions in older people. Br J Clin Pharmacol. 2018;84:2600\u201314.","journal-title":"Br J Clin Pharmacol"},{"key":"2532_CR22","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s12913-020-5056-3","volume":"20","author":"EK Crowley","year":"2020","unstructured":"Crowley EK, Sallevelt BTGM, Huibers CJA, Murphy KD, Spruit M, Shen Z, et al. Intervention protocol: OPtimising thERapy to prevent avoidable hospital admission in the multi-morbid elderly (OPERAM): a structured medication review with support of a computerised decision support system. BMC Health Serv Res. 2020;20:220.","journal-title":"BMC Health Serv Res"},{"key":"2532_CR23","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/jep.12787","volume":"24","author":"AC Drenth-van Maanen","year":"2018","unstructured":"Drenth-van Maanen AC, Leendertse AJ, Jansen PAF, Knol W, Keijsers CJPW, Meulendijk MC, et al. The systematic tool to reduce inappropriate prescribing (STRIP): combining implicit and explicit prescribing tools to improve appropriate prescribing. J Eval Clin Pract. 2018;24:317\u201322.","journal-title":"J Eval Clin Pract"},{"key":"2532_CR24","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2165\/00002512-200825040-00007","volume":"25","author":"LR Tulner","year":"2008","unstructured":"Tulner LR, Frankfort SV, Gijsen GJPT, van Campen JPCM, Koks CHW, Beijnen JH. Drug-drug interactions in a geriatric outpatient cohort: prevalence and relevance. Drugs Aging. 2008;25:343\u201355.","journal-title":"Drugs Aging"},{"key":"2532_CR25","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1002\/pds.2224","volume":"20","author":"W Hoffmann","year":"2011","unstructured":"Hoffmann W, van den Berg N, Thyrian JR, Fiss T. Frequency and determinants of potential drug-drug interactions in an elderly population receiving regular home visits by GPs--results of the home medication review in the AGnES-studies. Pharmacoepidemiol Drug Saf. 2011;20:1311\u20138.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2532_CR26","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/pds.3510","volume":"22","author":"L Pasina","year":"2013","unstructured":"Pasina L, Djade CD, Nobili A, Tettamanti M, Franchi C, Salerno F, et al. Drug-drug interactions in a cohort of hospitalized elderly patients. Pharmacoepidemiol Drug Saf. 2013;22:1054\u201360.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2532_CR27","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/1472-6963-7-147","volume":"7","author":"SV Doubova Dubova","year":"2007","unstructured":"Doubova Dubova SV, Reyes-Morales H, del Torres-Arreola L. P, Su\u00e1rez-Ortega M. potential drug-drug and drug-disease interactions in prescriptions for ambulatory patients over 50 years of age in family medicine clinics in Mexico City. BMC Health Serv Res. 2007;7:147.","journal-title":"BMC Health Serv Res"},{"key":"2532_CR28","doi-asserted-by":"crossref","unstructured":"Toivo TM, Mikkola J a. V, Laine K, Airaksinen M. Identifying high risk medications causing potential drug-drug interactions in outpatients: A prescription database study based on an online surveillance system. Res Soc Adm Pharm. 2016;12:559\u201368.","DOI":"10.1016\/j.sapharm.2015.09.004"},{"key":"2532_CR29","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s00228-014-1745-3","volume":"70","author":"J Holm","year":"2014","unstructured":"Holm J, Eiermann B, Eliasson E, Mannheimer B. A limited number of prescribed drugs account for the great majority of drug-drug interactions. Eur J Clin Pharmacol. 2014;70:1375\u201383.","journal-title":"Eur J Clin Pharmacol"},{"key":"2532_CR30","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.ejim.2007.12.002","volume":"19","author":"P Vonbach","year":"2008","unstructured":"Vonbach P, Dubied A, Kr\u00e4henb\u00fchl S, Beer JH. Prevalence of drug-drug interactions at hospital entry and during hospital stay of patients in internal medicine. Eur J Intern Med. 2008;19:413\u201320.","journal-title":"Eur J Intern Med"},{"key":"2532_CR31","doi-asserted-by":"publisher","first-page":"504","DOI":"10.5414\/CPP38504","volume":"38","author":"GI K\u00f6hler","year":"2000","unstructured":"K\u00f6hler GI, Bode-B\u00f6ger SM, Busse R, Hoopmann M, Welte T, B\u00f6ger RH. Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther. 2000;38:504\u201313.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2532_CR32","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s00228-007-0326-0","volume":"63","author":"E Astrand","year":"2007","unstructured":"Astrand E, Astrand B, Antonov K, Petersson G. Potential drug interactions during a three-decade study period: a cross-sectional study of a prescription register. Eur J Clin Pharmacol. 2007;63:851\u20139.","journal-title":"Eur J Clin Pharmacol"},{"key":"2532_CR33","doi-asserted-by":"publisher","first-page":"e0211695","DOI":"10.1371\/journal.pone.0211695","volume":"14","author":"L Zerah","year":"2019","unstructured":"Zerah L, Bun R-S, Guillo S, Collet J-P, Bonnet-Zamponi D, Tubach F. A prescription support-tool for chronic management of oral antithrombotic combinations in adults based on a systematic review of international guidelines. PloS One. 2019;14:e0211695.","journal-title":"PloS One"},{"key":"2532_CR34","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1007\/s00228-013-1531-7","volume":"69","author":"S Marusic","year":"2013","unstructured":"Marusic S, Bacic-Vrca V, Obreli Neto PR, Franic M, Erdeljic V, Gojo-Tomic N. Actual drug-drug interactions in elderly patients discharged from internal medicine clinic: a prospective observational study. Eur J Clin Pharmacol. 2013;69:1717\u201324.","journal-title":"Eur J Clin Pharmacol"},{"key":"2532_CR35","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s00228-004-0830-4","volume":"60","author":"HS Blix","year":"2004","unstructured":"Blix HS, Viktil KK, Reikvam A, Moger TA, Hjemaas BJ, Pretsch P, et al. The majority of hospitalised patients have drug-related problems: results from a prospective study in general hospitals. Eur J Clin Pharmacol. 2004;60:651\u20138.","journal-title":"Eur J Clin Pharmacol"}],"container-title":["BMC Geriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-021-02532-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12877-021-02532-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-021-02532-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T09:52:32Z","timestamp":1699696352000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgeriatr.biomedcentral.com\/articles\/10.1186\/s12877-021-02532-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,18]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2532"],"URL":"https:\/\/doi.org\/10.1186\/s12877-021-02532-z","relation":{},"ISSN":["1471-2318"],"issn-type":[{"value":"1471-2318","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,18]]},"assertion":[{"value":"6 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the independent research ethics committees at each site (lead ethics committee: Cantonal Ethics Committee Bern, Switzerland, ID 2016\u201301200; Medical Research Ethics Committee Utrecht, Netherlands, ID 15\u2013522\/D; Comit\u00e9 d\u2019Ethique Hospitalo-Facultaire Saint-Luc-UCL: 2016\/20JUL\/347\u2013Belgian registration No: B403201629175; Cork University Teaching Hospitals Clinical Ethics Committee, Cork, Republic of Ireland; ID ECM 4 (o) 07\/02\/17), and Swissmedic as responsible regulatory authority. Written informed consent was obtained from the patients or their legal representatives before enrolment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"571"}}